Multiple Myeloma (MM) is a disease affecting certain blood cells in the bone. This study tests a new drug called **ABBV-438** for adults with MM that has returned or isn't responding to treatment. The drug is given through an **intravenous (IV)** line, which means it's delivered directly into your vein.
The study has two parts: Part 1 finds the best dose, and Part 2 confirms it. About 127 adults worldwide will join, with each getting ABBV-438 in multiple doses. The study lasts about 69.5 months, and participants will need to visit a hospital or clinic regularly. Doctors will check your health through different tests like blood work and questionnaires.
- Study length is nearly 70 months with regular hospital visits.
- Participants will receive medication through an IV.
- Higher treatment burden may occur compared to regular treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand